- Financial Times•yesterday
Biotech can easily get overshadowed by its larger and more profit-generating cousin, big pharma. However, the symbiosis between the two sectors has never been greater. Previously the small companies, usually ...
- Zacks•2 days ago
AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.
- Investor's Business Daily•2 days ago
The U.K. drug giant reported higher adjusted EPS even as sales continued to fall. AstraZeneca is pinning its hopes on a key immunotherapy drug trial.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,595.00 x 6100|
|Ask||4,699.00 x 13000|
|Day's Range||4,614.00 - 4,762.41|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||16.80|
|Dividend & Yield||2.80 (4.81%)|
|1y Target Est||N/A|